A CIMT is an ultrasound test that measures the thickness of the two inner layers of your carotid arteries, the large blood vessels on each side of your neck that supply blood to your brain. The test is used to detect early signs of atherosclerosis, the buildup of plaque inside artery walls, sometimes years before symptoms appear. It’s noninvasive, painless, and takes about 8 minutes.
What the Test Actually Measures
Your artery wall has three layers. The innermost layer, called the intima, is in direct contact with your blood. Just outside it sits the media, a muscular middle layer. CIMT measures the combined thickness of these two layers. When plaque starts to build up, these layers get thicker. Because this thickening begins before the artery narrows enough to cause problems, CIMT can theoretically catch atherosclerosis at its earliest stage.
A typical measurement in adults falls around 0.5 to 0.6 millimeters. Values above 0.7 mm are generally considered elevated. But interpreting results isn’t straightforward because normal thickness varies by age, sex, and ethnicity, and different testing protocols can produce different numbers for the same artery.
What Happens During the Test
You lie on your back while a technician places an ultrasound probe on your neck. You’ll turn your head to one side so the technician can get a clear view of the carotid artery on the opposite side, then repeat for the other side. The probe uses high-frequency sound waves to produce a real-time image of your artery wall. The technician captures measurements from multiple angles to get an accurate picture of the wall thickness.
There’s no needle, no injection, no radiation, and no preparation required. The whole process typically wraps up in under 10 minutes.
Why a Doctor Might Suggest One
CIMT is sometimes recommended for people who fall into a gray area for heart disease risk. Standard risk calculators use factors like age, cholesterol, blood pressure, smoking status, and diabetes to estimate your chance of having a heart attack or stroke in the next 10 years. When those calculators put someone in a borderline or intermediate risk category, a doctor may want additional information to decide whether to start preventive treatment like a statin.
The idea behind CIMT is that it could provide that extra information by showing whether plaque is already forming, even when traditional numbers look only mildly concerning. It has also been used in research settings to track whether treatments are slowing the progression of atherosclerosis over time.
What Major Guidelines Say
Here’s where it gets complicated. Both the American Heart Association and the American College of Cardiology do not recommend CIMT for routine cardiovascular risk assessment. Their 2021 guidelines cite two main reasons: a lack of standardized testing methods across clinics, and limited evidence that CIMT results improve predictions beyond what traditional risk factors already tell you.
A large study called the Multi-Ethnic Study of Atherosclerosis followed initially healthy adults for over five years. Adding CIMT measurements to standard risk factors barely moved the needle on prediction accuracy. The statistical measure of predictive power was 0.77 with risk factors alone and 0.78 with CIMT added, a difference too small to be meaningful. Other studies have reached similar conclusions.
For people in that borderline or intermediate risk zone, guidelines instead recommend coronary artery calcium scoring as the preferred additional test.
CIMT vs. Coronary Artery Calcium Scoring
These two tests look for different stages of the same disease. CIMT uses ultrasound to detect thickening in the neck arteries, which can reflect early, soft plaque that hasn’t yet hardened. Coronary artery calcium scoring uses a CT scan to measure calcified plaque in the heart’s own arteries. Calcification represents a more advanced stage of vascular disease.
The two measurements don’t correlate well with each other, and that gap reveals something important. In one study, nearly half of patients who had a calcium score of zero, which would normally be reassuring, still showed signs of atherosclerosis on carotid ultrasound. About a third had visible plaque in their carotid arteries. This means a clean calcium score doesn’t necessarily rule out earlier-stage disease. For younger or middle-aged adults whose plaque hasn’t calcified yet, CIMT could theoretically catch what a calcium score misses.
Accuracy and Limitations
The biggest weakness of CIMT is inconsistency. There is no single universal protocol for how the test should be performed. Different clinics may measure at different spots along the artery, use different angles, and apply different software to read the images. The same measurement could be classified as normal at one facility and abnormal at another.
Operator skill matters significantly. Manual measurement methods introduce more subjectivity than automated or semi-automated software, which is why newer systems rely on computer-assisted readings to reduce human error. Even the timing of the measurement within a single heartbeat can shift results by 5% to 10%, so some protocols synchronize readings with an electrocardiogram to standardize the moment of capture.
Variability between different technicians reading the same scan runs about 0.13 to 0.20 mm, which is substantial when the difference between a normal and elevated reading might be just a fraction of a millimeter. Anatomical differences between patients, such as neck shape and artery positioning, also affect how clearly the artery wall shows up on ultrasound.
Insurance Coverage
Most private insurers consider CIMT experimental or unproven and do not cover it. Cigna’s coverage policy, for example, classifies it as investigational for all indications, including heart disease risk assessment. Medicare has no national or local coverage determination for the test, which effectively means it isn’t covered under standard Medicare benefits either. If you get a CIMT scan, expect to pay out of pocket unless your state has a specific mandate requiring coverage. Some preventive health clinics and imaging centers offer it as an elective screening, often marketed directly to patients.